Literature DB >> 28203412

Predictive models of malignant transudative pleural effusions.

Lucía Ferreiro1, Francisco Gude2, María E Toubes3, Adriana Lama3, Juan Suárez-Antelo3, Esther San-José4, Francisco Javier González-Barcala1, Antonio Golpe1, José M Álvarez-Dobaño1, Carlos Rábade3, Nuria Rodríguez-Núñez3, Carla Díaz-Louzao5, Luis Valdés3.   

Abstract

BACKGROUND: There are no firm recommendations when cytology should be performed in pleural transudates, since some malignant pleural effusions (MPEs) behave biochemically as transudates. The objective was to assess when would be justified to perform cytology on pleural transudates.
METHODS: Consecutive patients with transudative pleural effusion (PE) were enrolled and divided in two groups: malignant and non-MPE. Logistic regression analysis was used to estimate the probability of malignancy. Two prognostic models were considered: (I) clinical-radiological variables; and (II) combination of clinical-radiological and analytical variables. Calibration and discrimination [receiver operating characteristics (ROC) curves and area under the curve (AUC)] were performed.
RESULTS: A total of 281 pleural transudates were included: 26 malignant and 255 non-malignant. The AUC obtained with Model 1 (left PE, radiological images compatible with malignancy, absence of dyspnea, and serosanguinous appearance of the fluid), and Model 2 (the variables of Model 1 plus CEA) were 0.973 and 0.995, respectively. Although no false negatives are found in Models 1 and 2 to probabilities of 11% and 14%, respectively, by applying bootstrapping techniques to not find false negatives in 95% of other possible samples would require lowering the cut-off points for the aforementioned probabilities to 3% (Model 1) and 4% (Model 2), respectively. The false positive results are 32 (Model 1) and 18 (Model 2), with no false negatives.
CONCLUSIONS: The applied models have a high discriminative ability to predict when a transudative PE may be of neoplastic origin, being superior to adding an analytical variable to the clinic-radiological variables.

Entities:  

Keywords:  Pleural effusion (PE); cytology; malignant; thoracentesis

Year:  2017        PMID: 28203412      PMCID: PMC5303099          DOI: 10.21037/jtd.2017.01.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  31 in total

1.  Cytology on transudative pleural effusions.

Authors:  B Teklu
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

2.  Clinical practice. Pleural effusion.

Authors:  Richard W Light
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 3.  [Diagnosis and treatment of pleural effusion].

Authors:  Victoria Villena Garrido; Jaime Ferrer Sancho; Luis Hernández Blasco; Alicia de Pablo Gafas; Esteban Pérez Rodríguez; Francisco Rodríguez Panadero; Santiago Romero Candeira; Angel Salvatierra Velázquez; Luis Valdés Cuadrado
Journal:  Arch Bronconeumol       Date:  2006-07       Impact factor: 4.872

4.  Cytologically proved malignant pleural effusions.

Authors:  D J Castro; G D Nuevo; E Perez-Rodriguez
Journal:  Chest       Date:  1998-12       Impact factor: 9.410

5.  Developing a 'pleural team' to run a reactive pleural service.

Authors:  Rahul Bhatnagar; Nick Maskell
Journal:  Clin Med (Lond)       Date:  2013-10       Impact factor: 2.659

6.  Cytologically proved malignant pleural effusions: distribution of transudates and exudates.

Authors:  Z Assi; J L Caruso; J Herndon; E F Patz
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

7.  Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients.

Authors:  F Llach; A I Arieff; S G Massry
Journal:  Ann Intern Med       Date:  1975-07       Impact factor: 25.391

Review 8.  Pleural effusions.

Authors:  Richard W Light
Journal:  Med Clin North Am       Date:  2011-09-25       Impact factor: 5.456

Review 9.  Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.

Authors:  Q-L Liang; H-Z Shi; X-J Qin; X-D Liang; J Jiang; H-B Yang
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

10.  Combining clinical and analytical parameters improves prediction of malignant pleural effusion.

Authors:  Luis Valdés; Esther San-José; Lucía Ferreiro; Francisco-Javier González-Barcala; Antonio Golpe; José M Álvarez-Dobaño; María E Toubes; Nuria Rodríguez-Núñez; Carlos Rábade; Adriana Lama; Francisco Gude
Journal:  Lung       Date:  2013-10-02       Impact factor: 2.584

View more
  6 in total

1.  Diagnosing malignant pleural effusion using clinical and analytical parameters.

Authors:  Yong Pan; Wenjing Bai; Jiangnan Chen; Yijian Mao; Xiaohong Qian; Ke Xu; Shaohua Tang; Junwu Zhang; Chong Chen; Jingyi Chen; Xingzhong Hu
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

2.  Significance of congestive heart failure as a cause of pleural effusion: Pilot data from a large multidisciplinary teaching hospital.

Authors:  Piotr Korczyński; Katarzyna Górska; Damian Konopka; Dżamila Al-Haj; Krzysztof J Filipiak; Rafał Krenke
Journal:  Cardiol J       Date:  2018-11-08       Impact factor: 2.737

3.  Transudative pleural effusion of malignant etiology: Rare but real.

Authors:  Lindsey Johnson; Hafiz Abdul Moiz Fakih; Salim Daouk; Shaheera Saleem; Ali Ataya
Journal:  Respir Med Case Rep       Date:  2017-02-28

Review 4.  Malignant Pleural Effusion: Diagnosis and Management.

Authors:  Lucía Ferreiro; Juan Suárez-Antelo; José Manuel Álvarez-Dobaño; María E Toubes; Vanessa Riveiro; Luis Valdés
Journal:  Can Respir J       Date:  2020-09-23       Impact factor: 2.409

Review 5.  Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review.

Authors:  Blake Jacobs; Ghias Sheikh; Houssein A Youness; Jean I Keddissi; Tony Abdo
Journal:  Diagnostics (Basel)       Date:  2022-04-18

6.  Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial.

Authors:  Maribel Botana-Rial; Lorena Vázquez-Iglesias; Pedro Casado-Rey; María Páez de la Cadena; María Amalia Andrade-Olivié; José Abal-Arca; Laura García-Nimo; Lucía Ferreiro-Fernández; Luis Valdés-Cuadrado; María Esther San-José; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.